FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295226740> ?p ?o ?g. }

• W4295226740 endingPage "S177" @default.
• W4295226740 startingPage "S177" @default.
• W4295226740 abstract "Objectives: To examine trends and outcomes related to sentinel lymph node (SLN) biopsy for stage II endometrial cancer. Methods: This is a retrospective observational cohort study querying the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. The study population was 6,314 women with T2 endometrial cancer who underwent hysterectomy from 2010-2018. Exposure allocation was based on nodal evaluation type: lym- phadenectomy (LND; n=4,915, 77.8%), SLN biopsy (n=340, 5.4%), or no surgical nodal evaluation (n=1,059, 16.8%). The main outcomes were (i) trends and characteristics related to nodal evaluation assessed by multinomial regression and (ii) overall survival assessed by an inverse probability of treatment weighting propensity score analysis. A sensitivity analysis was performed to examine concurrent LND in women who underwent SLN biopsy. Results: The utilization of SLN biopsy increased from 1.6% to 16.1%, while the number of LND decreased from 81.5% to 65.7% between 2010 and 2018 (both, p<0.05). In multivariable analysis, the utilization of SLN biopsy increased 45% annually (adjusted-odds ratio: 1.45, 95% CI: 1.37-1.54, p<0.001). The frequency of SLN biopsy alone exceeded the frequency of SLN biopsy with concurrent LND in 2017 (6.8% vs 3.4%), followed by a continued increase in SLN biopsy alone (11.2% vs 4.9%) in 2018. In the weighted model, the 3-year overall survival rate was 79.9% for the SLN biopsy group and 78.6% for the LND group (HR: 0.98, 95% Cl: 0.80-1.20, p=0.831). Similarly, the SLN biopsy alone without a concurrent performance of LND had comparable overall survival compared to the LND group (HR: 0.90, 95% CI: 0.59-1.36, p=0.615). Conclusions: Utilization of SLN biopsy in stage II endometrial cancer increased significantly over time, and SLN biopsy-incorporated nodal assessment was not associated with worsened short-term survival. Objectives: To examine trends and outcomes related to sentinel lymph node (SLN) biopsy for stage II endometrial cancer. Methods: This is a retrospective observational cohort study querying the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. The study population was 6,314 women with T2 endometrial cancer who underwent hysterectomy from 2010-2018. Exposure allocation was based on nodal evaluation type: lym- phadenectomy (LND; n=4,915, 77.8%), SLN biopsy (n=340, 5.4%), or no surgical nodal evaluation (n=1,059, 16.8%). The main outcomes were (i) trends and characteristics related to nodal evaluation assessed by multinomial regression and (ii) overall survival assessed by an inverse probability of treatment weighting propensity score analysis. A sensitivity analysis was performed to examine concurrent LND in women who underwent SLN biopsy. Results: The utilization of SLN biopsy increased from 1.6% to 16.1%, while the number of LND decreased from 81.5% to 65.7% between 2010 and 2018 (both, p<0.05). In multivariable analysis, the utilization of SLN biopsy increased 45% annually (adjusted-odds ratio: 1.45, 95% CI: 1.37-1.54, p<0.001). The frequency of SLN biopsy alone exceeded the frequency of SLN biopsy with concurrent LND in 2017 (6.8% vs 3.4%), followed by a continued increase in SLN biopsy alone (11.2% vs 4.9%) in 2018. In the weighted model, the 3-year overall survival rate was 79.9% for the SLN biopsy group and 78.6% for the LND group (HR: 0.98, 95% Cl: 0.80-1.20, p=0.831). Similarly, the SLN biopsy alone without a concurrent performance of LND had comparable overall survival compared to the LND group (HR: 0.90, 95% CI: 0.59-1.36, p=0.615). Conclusions: Utilization of SLN biopsy in stage II endometrial cancer increased significantly over time, and SLN biopsy-incorporated nodal assessment was not associated with worsened short-term survival." @default.
• W4295226740 created "2022-09-12" @default.
• W4295226740 creator A5000713007 @default.
• W4295226740 creator A5031622882 @default.
• W4295226740 creator A5037820269 @default.
• W4295226740 creator A5043916697 @default.
• W4295226740 creator A5057686070 @default.
• W4295226740 creator A5075566972 @default.
• W4295226740 creator A5084740139 @default.
• W4295226740 date "2022-08-01" @default.
• W4295226740 modified "2023-10-10" @default.
• W4295226740 title "Sentinel lymph node biopsy for stage II endometrial cancer: Utilization and outcomes in the United States (346)" @default.
• W4295226740 doi "https://doi.org/10.1016/s0090-8258(22)01568-2" @default.
• W4295226740 hasPublicationYear "2022" @default.
• W4295226740 type Work @default.
• W4295226740 citedByCount "0" @default.
• W4295226740 crossrefType "journal-article" @default.
• W4295226740 hasAuthorship W4295226740A5000713007 @default.
• W4295226740 hasAuthorship W4295226740A5031622882 @default.
• W4295226740 hasAuthorship W4295226740A5037820269 @default.
• W4295226740 hasAuthorship W4295226740A5043916697 @default.
• W4295226740 hasAuthorship W4295226740A5057686070 @default.
• W4295226740 hasAuthorship W4295226740A5075566972 @default.
• W4295226740 hasAuthorship W4295226740A5084740139 @default.
• W4295226740 hasConcept C121608353 @default.
• W4295226740 hasConcept C126322002 @default.
• W4295226740 hasConcept C126894567 @default.
• W4295226740 hasConcept C156957248 @default.
• W4295226740 hasConcept C167135981 @default.
• W4295226740 hasConcept C2775934546 @default.
• W4295226740 hasConcept C2777088508 @default.
• W4295226740 hasConcept C2780212769 @default.
• W4295226740 hasConcept C2908647359 @default.
• W4295226740 hasConcept C29456083 @default.
• W4295226740 hasConcept C530470458 @default.
• W4295226740 hasConcept C71924100 @default.
• W4295226740 hasConcept C99454951 @default.
• W4295226740 hasConceptScore W4295226740C121608353 @default.
• W4295226740 hasConceptScore W4295226740C126322002 @default.
• W4295226740 hasConceptScore W4295226740C126894567 @default.
• W4295226740 hasConceptScore W4295226740C156957248 @default.
• W4295226740 hasConceptScore W4295226740C167135981 @default.
• W4295226740 hasConceptScore W4295226740C2775934546 @default.
• W4295226740 hasConceptScore W4295226740C2777088508 @default.
• W4295226740 hasConceptScore W4295226740C2780212769 @default.
• W4295226740 hasConceptScore W4295226740C2908647359 @default.
• W4295226740 hasConceptScore W4295226740C29456083 @default.
• W4295226740 hasConceptScore W4295226740C530470458 @default.
• W4295226740 hasConceptScore W4295226740C71924100 @default.
• W4295226740 hasConceptScore W4295226740C99454951 @default.
• W4295226740 hasLocation W42952267401 @default.
• W4295226740 hasOpenAccess W4295226740 @default.
• W4295226740 hasPrimaryLocation W42952267401 @default.
• W4295226740 hasRelatedWork W1976492496 @default.
• W4295226740 hasRelatedWork W1996914930 @default.
• W4295226740 hasRelatedWork W2106376036 @default.
• W4295226740 hasRelatedWork W2330864342 @default.
• W4295226740 hasRelatedWork W2417523550 @default.
• W4295226740 hasRelatedWork W3119169953 @default.
• W4295226740 hasRelatedWork W3165680200 @default.
• W4295226740 hasRelatedWork W3210025551 @default.
• W4295226740 hasRelatedWork W3212538320 @default.
• W4295226740 hasRelatedWork W4235961256 @default.
• W4295226740 hasVolume "166" @default.
• W4295226740 isParatext "false" @default.
• W4295226740 isRetracted "false" @default.
• W4295226740 workType "article" @default.